Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions

Metabolism: Clinical and Experimental
M K Chan

Abstract

Twenty-five CAPD patients were given gemfibrozil in increasing doses for a total of 14 weeks. Parameters of lipid metabolism including serum total cholesterol, LDL cholesterol, HDL cholesterol, HDL2 cholesterol, HDL3 cholesterol triglyceride, apolipoprotein A-1, apolipoprotein B, postheparin lipoprotein lipase, and hepatic lipase activities were measured before the commencement, at every increment in the dose of gemfibrozil and 4 weeks after discontinuation of therapy. Gemfibrozil normalized the deranged parameters of lipid metabolism. Thus, with treatment, serum triglyceride, and total cholesterol, LDL cholesterol and apo B decreased, whereas serum HDL cholesterol, HDL2, and HDL3 (predominantly the latter subfraction), hepatic lipoprotein lipase activities increased. Apo A-1 did not change significantly. Even in normotriglyceridemic patients serum HDL cholesterol increased. The side effects consisted of muscle aches and a significant rise in serum CPK. Gemfibrozil produced a significant decrease in gamma-GT activities. A possible mechanism for the interconversion between HDL2 and HDL3 that resulted in a preferential increase in the latter was discussed. It was concluded that gemfibrozil, in a dose not exceeding 300 mg twice a ...Continue Reading

References

Jun 1, 1976·Metabolism: Clinical and Experimental·J J AlbersJ J Hoover
Jul 15, 1986·Clinica Chimica Acta; International Journal of Clinical Chemistry·Y TalamehH Naito
Jul 1, 1987·Sports Medicine·T D Noakes
Sep 1, 1987·Sports Medicine·L Goldberg, D L Elliot
Jan 1, 1986·Acta Medica Scandinavica·B Lindholm, H E Norbeck
Dec 1, 1984·The Journal of Clinical Investigation·J R PatschG Bengtsson-Olivecrona
May 1, 1981·Kidney International·M K ChanJ F Moorhead
Feb 26, 1982·Clinica Chimica Acta; International Journal of Clinical Chemistry·M K ChanJ F Moorhead

❮ Previous
Next ❯

Citations

Aug 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Mark E Molitch
Jan 1, 1993·Scandinavian Journal of Urology and Nephrology·M S ElisafK C Siamopoulos
Sep 15, 2006·Seminars in Dialysis·Jia LiuMitchell H Rosner
Feb 1, 1994·Metabolism: Clinical and Experimental·A BaldoK Cianflone
Dec 1, 1990·Baillière's Clinical Endocrinology and Metabolism·C D Short, P N Durrington
Aug 1, 1994·Atherosclerosis·A GawJ Shepherd
Oct 1, 1992·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·C R SirtoriG Franceschini
Jul 1, 1995·Kidney International·Z A MassyB L Kasiske

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.